Final-Program-ATS-2023-AP.vp

224

TUESDAY • MAY 23

BASIC MINI SYMPOSIUM

BEHAVIORAL • CLINICAL MINI SYMPOSIUM

C13

C14

CYTOKINES: CYTOKINES IN THE AIRWAYS

SOCIAL DETERMINANTS OF HEALTH AND TREATMENT OF ASTHMA

9:00 a.m. - 11:00 a.m.

Marriott Marquis Downtown Independence Ballroom Salons A-D (Level M4)

9:00 a.m. - 11:00 a.m.

Walter E. Washington Convention Center Room 204 A-C (Level 2)

Chairing: J. Alexander-Brett, MD, PhD, Saint Louis, MO M. Gauthier, MD, Pittsburgh, PA D.P. Albon, MD, Charlottesville, VA Oral Presentations: 9:00 Loss of CFTR Reprograms Airway Epithelial IL-33 Release and Regulates IL-33 Dependent Inflammation/ D.P. Cook, Nashville, TN 9:12 Inhibition of Macrophage Migration Inhibitory Factor Signaling Prevents SARS-CoV-2 Infection/ S.-J. Kim, Durham, NC 9:24 Interleukin-33 (IL-33) Drives Type 1 and Type 2 Inflammation and Instructs Airway Remodeling/ S. Srivatsan, Tarrytown, NY 9:36 N-terminal Truncated Forms of the Cytokine IL-36 g Derived From Host Proteases Induce Airspace Neutrophil Recruitment and CXCL-5 Production in the Lung/ M. Tabary, Pittsburgh, PA 9:48 IL-18 Receptor-deficient Mice Have Enhanced Airway Hyperresponsiveness and Eosinophilia in a Model of Allergic Asthma/ R. Murphy, Seattle, WA 10:00 Lung Lavage Cytokine Signatures in Preschool Children With Problematic Wheeze Infected With Rhinovirus Supports M1 and M2 Alveolar Macrophage Activation/ W.G. Teague, Charlottesville, VA 10:12 IL-13 Induces Epigenetic Inflammatory Memory in a Subset of Airway Stem Cell Clones/ G.C. Necker, Iowa City, IA 10:24 Itepekimab Binds to IL-33 With High Affinity, Prevents the Formation of IL-33/ST2/IL-1RAcP Signaling Complex and Blocks Mediators of Airway Inflammation/ S. Asrat, Tarrytown, NY 10:36 Hillock Cells Are Immunoresponsive Airway Epithelial Cells That Promote Type 2 Inflammation and Barrier Dysfunction in Asthmatics/ J. Alladina, Boston, MA

Chairing: A.A. Pappalardo, MD, Chicago, IL A. Volerman, MD, Chicago, IL L.B. Gerald, PhD, MSPH, Chicago, IL Oral Presentations: 9:00 Markedly Higher Healthcare Utilization and Poor Disease Control Among Patients With Asthma-COPD Overlap Compared to Patients With Each Disease Alone/ M.W. Sjoding, Ann Arbor, MI 9:12 Severe Asthma Exacerbations Across Disease Severities: Which Patients Are at Greatest Risk?/ N.L. Lugogo, Ann Arbor, MI 9:24 Cost-effectiveness of a Portable HEPA Air Cleaner Distribution Program to Reduce Asthma Complications in British Columbia/ C. Carlsten, Vancouver, Canada 9:36 Intensive Pest Management With HEPA Air Filtration Is a Cost-effective Intervention That Reduces Asthma Morbidity in Inner City Public Schools/ C. Socolovsky, Boston, MA 9:48 Addressing Social Determinants of Health in Pediatric Asthma Care Through School-supervised Therapy: Perspectives From Participants and Community Partners/ L. Al-Halbouni, Worcester, MA 10:00 The Sleep Environment, Napping, and Sleep Outcomes Among Urban Children With and Without Asthma/ A.J. Yeo, Providence, RI 10:12 Pediatric Psychosocial Problems and Asthma Symptoms in an Urban Environment/ R. Koehl, Baltimore, MD 10:24 Differences in Asthma Self-management Education Between English and Spanish Respondents: Findings From the 2017-2019 U.S. Asthma Call Back Survey/ J.D. Rose, Philadelphia, PA 10:36 Comparative Effectiveness of Omalizumab, Mepolizumab, Benralizumab, and Dupilumab for Asthma in a Matched Retrospective Cohort/ A. Akenroye, Boston, MA 10:48 Cost Analyses of a Symptom-driven Inhaled Corticosteroid-Formoterol Treatment Strategy for Patients With Mild Asthma From a United States Payor Perspective/ C.J. Renaud, St. Louis, MO

ATS 2023 • Washington, DC